Literature DB >> 27449616

Viral Vectors for Gene Therapy: Current State and Clinical Perspectives.

A N Lukashev1, A A Zamyatnin.   

Abstract

Gene therapy is the straightforward approach for the application of recent advances in molecular biology into clinical practice. One of the major obstacles in the development of gene therapy is the delivery of the effector to and into the target cell. Unfortunately, most methods commonly used in laboratory practice are poorly suited for clinical use. Viral vectors are one of the most promising methods for gene therapy delivery. Millions of years of evolution of viruses have resulted in the development of various molecular mechanisms for entry into cells, long-term survival within cells, and activation, inhibition, or modification of the host defense mechanisms at all levels. The relatively simple organization of viruses, small genome size, and evolutionary plasticity allow modifying them to create effective instruments for gene therapy approaches. This review summarizes the latest trends in the development of gene therapy, in particular, various aspects and prospects of the development of clinical products based on viral delivery systems.

Mesh:

Year:  2016        PMID: 27449616     DOI: 10.1134/S0006297916070063

Source DB:  PubMed          Journal:  Biochemistry (Mosc)        ISSN: 0006-2979            Impact factor:   2.487


  32 in total

1.  Novel nano-microspheres containing chitosan, hyaluronic acid, and chondroitin sulfate deliver growth and differentiation factor-5 plasmid for osteoarthritis gene therapy.

Authors:  Zhu Chen; Shang Deng; De-Chao Yuan; Kang Liu; Xiao-Cong Xiang; Liang Cheng; Dong-Qin Xiao; Li Deng; Gang Feng
Journal:  J Zhejiang Univ Sci B       Date:  2018 Dec.       Impact factor: 3.066

2.  HIF1A overexpression using cell-penetrating DNA-binding protein induces angiogenesis in vitro and in vivo.

Authors:  Mijeong Jeon; Yooseok Shin; Jaeeun Jung; Ui-Won Jung; Jae-Hoon Lee; Jae-Seung Moon; Ilkoo Kim; Jin-Su Shin; Sang-Kyou Lee; Je Seon Song
Journal:  Mol Cell Biochem       Date:  2017-06-28       Impact factor: 3.396

Review 3.  Adenoviral vectors for in vivo delivery of CRISPR-Cas gene editors.

Authors:  Paul Boucher; Xiaoxia Cui; David T Curiel
Journal:  J Control Release       Date:  2020-09-03       Impact factor: 9.776

Review 4.  Engineering new neurons: in vivo reprogramming in mammalian brain and spinal cord.

Authors:  Lei-Lei Wang; Chun-Li Zhang
Journal:  Cell Tissue Res       Date:  2017-11-23       Impact factor: 5.249

5.  The intersectional genetics landscape for humans.

Authors:  Andre Macedo; Alisson M Gontijo
Journal:  Gigascience       Date:  2020-08-01       Impact factor: 6.524

6.  A simple protocol for transfecting human mesenchymal stem cells.

Authors:  Talita Giacomet de Carvalho; Felipe Matheus Pellenz; Alvaro Laureano; Lucia Mariano da Rocha Silla; Roberto Giugliani; Guilherme Baldo; Ursula Matte
Journal:  Biotechnol Lett       Date:  2018-01-17       Impact factor: 2.461

7.  General Characteristics of Microbubble-Adenovirus Vectors Carrying Genes.

Authors:  Lingjie Yang; Juan Ma; Lina Guan; Yuming Mu
Journal:  Cell Mol Bioeng       Date:  2020-11-30       Impact factor: 2.321

8.  Peptide-guided JC polyomavirus-like particles specifically target bladder cancer cells for gene therapy.

Authors:  Wei-Hong Lai; Chiung-Yao Fang; Ming-Chieh Chou; Mien-Chun Lin; Cheng-Huang Shen; Chun-Nun Chao; Yeong-Chin Jou; Deching Chang; Meilin Wang
Journal:  Sci Rep       Date:  2021-06-04       Impact factor: 4.379

Review 9.  Next Step in Gene Delivery: Modern Approaches and Further Perspectives of AAV Tropism Modification.

Authors:  Maxim A Korneyenkov; Andrey A Zamyatnin
Journal:  Pharmaceutics       Date:  2021-05-19       Impact factor: 6.321

10.  Proangiogenic Effect of 2A-Peptide Based Multicistronic Recombinant Constructs Encoding VEGF and FGF2 Growth Factors.

Authors:  Dilara Z Gatina; Ekaterina E Garanina; Margarita N Zhuravleva; Gulnaz E Synbulatova; Adelya F Mullakhmetova; Valeriya V Solovyeva; Andrey P Kiyasov; Catrin S Rutland; Albert A Rizvanov; Ilnur I Salafutdinov
Journal:  Int J Mol Sci       Date:  2021-05-31       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.